The Certificate in Psychedelic-Assisted Therapies by Mind Medicine Institute (MMI CPAT) has been developed primarily to meet the anticipated demand for trained therapists to provide regulatory-approved and research-backed psychedelic-assisted therapies for the treatment of mental ill-health in Australia. It is also expected that trained clinicians will be needed to work in research trials as they expand in Australia.
The training certificate follows world best practice following review of current practices including protocols developed by MAPS and the REBUS model developed at Imperial College London.
The development of the MMI program has relied on significant collaboration with colleagues with considerable psychotherapeutic skill and knowledge. The teaching program incorporates live face-to-face lectures and webcasts, self-study and direct teaching of skills and experiential workshops led by this team. For more details of members of the teaching team please see below.
While incorporating the best of components from courses overseas, the Certificate in Psychedelic-Assisted Therapies is also offered in the spirit of respect and acknowledgement of the local context within Australia. The 2021 program is the very first course of its kind in the Southern Hemisphere.
Mind Medicine Institute has listened to feedback from people keen to participate and has developed the course length and requirements to be accessible to people who are travelling from all over Australia and beyond. We also understand the need to make the course as widely available as possible to working therapists, who have time and financial pressures shaping their capacity to meet the demands of the course.
The original courses require practical elements – participation in research programs, etc., which are not yet as widely available in Australia as overseas. Mind Medicine Institute has nonetheless been committed to maintaining the highest quality possible, and so the course presents academic, didactic and skills development components in a similar hybrid model of online, live and self-study components as the CIIS course. We expect that as the course grows and graduates establish themselves and more opportunities will arise, including the possibility of incorporating learning by placements, shadowing, etc.
We also offer a Psychological Support Service currently, part of which enables clinicians working in the field to access supervision and on-going professional development – more details below.
We are also aware that there is a very long history of traditional use of these substances (as well as others not as well known) and practices for various healing and spiritual growth purposes in every continent in the world. Teaching about this history is part of the course. Incorporating input from traditional practitioners from various sources is an ambition we hold with high value for the future as reality permits.
For now, our focus is to start with training therapists primarily focused on meeting the needs of the mental health crisis, working within research programs and a medically supported environment, and providing integrative and other therapeutic work with the users of these substances.
The course will take place over a period of 4 months, with:
Mind Medicine Institute’s Certificate in Psychedelic-Assisted Therapies is endorsed as professional development training by the Australian College of Rural and Remote Medicine (ACRRM), Australasian Society of Lifestyle Medicine, College of Mental Health Nurses, and is recognised as professional development and training for qualified members of the Australian Association of Psychologists Inc, Psychotherapy and Counselling Institute of Australia (PACFA) and the Australian & New Zealand College of Cannabinoid Practitioners. It may also form the basis of individual professional development and training plans. All our training courses and events can also be used to claim ongoing Continuing Professional Development (CPD) points in Australia through professional colleges (e.g. through the Australian Psychological Society, RANZCP, RACGP…).
Please check with your professional membership body for the appropriate category and number of points.
The Certificate in Psychedelic-Assisted Therapies course aims to build on skills already acquired and used by professionals working in various therapeutic contexts.
Upon completion of the course, students will be eligible to join our Register of Qualified CPAT Practitioners.
The register has three discrete levels of membership pertaining to the treatment model for MDMA-assisted therapy.
The foundation for this therapeutic approach was laid by Stan and Christina Grof, Leo Zeff, George Greer, Requa Tolbert, Ralph Metzner, and many others. The basic premise of this treatment approach is that the therapeutic effect is not due simply to the physiological effects of the medicine; rather, it is the result of an interaction between the effects of the medicine, the therapeutic setting and the mindsets of the participant and the therapists.
The model involves initial prescription, preparatory sessions, psychedelic-assisted psychotherapy sessions, and integrative follow-up sessions.
a) Prescribing practitioner: requiring a medical degree, registration with an appropriate professional body (AHPRA) and 3 years professional practice
b) Lead therapist: either a medical or psychological degree, registration with an appropriate professional body (AHPRA, PACFA, etc.) and 3 years professional practice
c) Support facilitator: (can practice only under the supervision of a or b and as support in medicine sessions) and is either
i. Allied health practitioners and affiliates with appropriate professional registration
ii. A Student practitioner
(Psychedelic-assisted therapists can be both prescribers and therapists if they hold both relevant medical and therapeutic qualifications.)
The focus of Mind Medicine Institute is on the clinical application of medicinal psilocybin and medicinal MDMA for certain classes of mental illness in a regulatory approved manner. At the current time, these treatments are only legally available in Australia in particular circumstances (which can differ from State to State), and then only after specific regulatory approvals have first been obtained. Given this legal position we cannot accept any person into the course if we believe, on reasonable grounds, that that person is using or intends to use, these treatments in breach of the law. We also cannot condone in any way the illegal use of these substances.
Application fee: $250 (non-refundable)
Course fee: $9000 (or $8000 upfront payment in full)
The funding is available for outstanding practitioners in financial need and those from rural, regional areas and/or those from indigenous or other diverse groups to support part of the tuition fees for the course. Some financial assistance is available on a competitive basis.
Please note: Financial assistance allocations are still available for our 2022 July intake.
Course 3 & 4: Sunday 13 February – Sunday 19 June 2022
Pre-reading: Will be emailed on 12 December 2021
Weekly online webinars on Sunday alternating mornings and evenings
|First meeting – VICTORIA & NSW:||13 February 2022|
|Final meeting – VICTORIA & NSW:||19 June 2022|
|Weekend Intensives – VICTORIA:||
|Weekend Intensives – NSW:||
|Week-long Intensive – VICTORIA:||29 May to 3 June 2022^|
|Week-long Intensive – NSW:||5 June to 10 June 2022^|
|Final submission of coursework – VICTORIA & NSW:||30 June 2022|
|Supervised practice:||To be arranged*|
Course 5 & 6: Sunday 17 July to Sunday 13 November 2022
Pre-reading: Will be emailed on 20 May 2022
|First meeting:||17 July 2022|
|Final meeting:||13 November 2022|
|Week-long Intensive:||27th Oct – 1st November 2022^ (Victoria)
10th – 15th November 2022^ (NSW)
|Final submission of coursework:||29 Nov 2022|
|Supervised practice:||To be arranged*|
* Subject to regulatory requirements
“Mind Medicine Australia continues to impress. I have completed various higher education qualifications, as well as the less formal experiential retreats and personal development courses, from the quirky, to the evidence based. The CPAT provides a holistic framework that encapsulates a strong academic approach and faculty with a truly authentic therapeutic model. It would not be an exaggeration to say that the CPAT is life changing.”
Kelly Rae, Psychotherapist, NSW
“The CPAT has exceeded all expectations I had when I applied. I highly recommend this course to anyone in the field. The expertise and networking are second to none. I feel part of something that will change the future of mental health in Australia.”
something that will change the future of mental health in Australia.” Vasileios Tsaikalis, Psychotherapist, NSW
“This weekend was the most rounded professional development I can remember doing – I felt nourished in mind, soul and body. Not usually a networker, I surprised myself by connecting with many people that I am sincerely looking forward to meeting again and hopefully working with in the future. Even though the programme was intense, I feel inspired not exhausted; I think this is because there was such a supportive and empathic group of facilitators and participants. My gratitude to Mind Medicine Australia – I’m wearing our T-shirt as I sit at the airport & type, just hoping for when someone asks me what this is all about!”
Dr Ria Leonard, Psychiatrist, NSW
“The most engaging, interesting and enjoyable course I have attended.”
Dr Eoin Wilson, Psychiatrist, NSW
The course to date has been priceless and an invaluable opportunity to be a part of the medicine work moving into the future. I cannot recommend it highly enough!
Jon Hart, Psychologist, QLD
In my 30 years of work as a psychologist, I have never attended such an engaging and informative course of this calibre. The lecturers are world class experts in the field providing not just theories but also practical teachings along with experiential training. This course broadens my mind and also my heart.
Maurizio Romano, Psychotherapist
The CPAT course is amazing. Never ever ever have I been so engrossed and hungry for knowledge. The calibre of the educators is exceptional. If you are thinking about doing this course do it without hesitation. It is the bomb.
Gareth Wild, Coaching/Couselling Psychologist
Download the testimonials from our first two intakes: Download pdf (276.9 KB) Last updated: Jul 25, 2022
Are open for intakes 3-6 (Applicants will be considered in order of receipt. We expect the program to be over-subscribed so please register early to avoid disappointment.)
Screening and interview/finalise applicants:
Your application is processed as received and contact is made directly to assess further and arrange an interview
Step 1: Complete the Application Form.
Step 2: Send your $250 application processing fee including your initial course fee ($8000 – discounted upfront full fee or $3000 part fee): Mind Medicine Australia via Paypal or Credit Card Payment (part of the application form).
Step 3: Applications will be screened, and if successful invited to an interview in July.
Step 4: Final decision, and invitation to join the course.
Nigel Denning MA, MPsych is a Counselling Psychologist, AHPRA registered supervisor and Managing Director of Integrative Psychology a Psychology/Psychiatry practice in East Melbourne. He is a former Family Violence Co-ordinator for Relationships Australia and is currently the Former Deputy President of the In Good Faith Foundation, an organisation that supports Institutional Abuse and cult survivors. Nigel is also a registered Neuro-psychotherapy supervisor with IAAN.
Nigel has been involved in Transpersonal Psychology and consciousness studies for over thirty years. He has studied extensively under Stanislav Grof MD and worked closely with Tav Sparks and Grof Transpersonal Training to develop training approaches to Holotropic breathwork and therapy influenced by this modality. Nigel also conducted one of the few peer reviewed research studies on HB.
Nigel teaches and has presented at numerous national and international conferences on state change technology, including medicine work. Nigel also has an established practice in Tibet Bon Dzogchen meditation under the guidance of Dr Daniel Brown of Harvard Medical School.
Dr Tra-ill Dowie is the Head of the Faculty of Psychotherapy at Ikon Institute Australia. Dr Dowie is the Chair of the Australian Counselling Association (ACA) Panel for Trauma Standards & Practice. Dr Dowie is a practising psychotherapist, supervisor and public speaker.
Dr Dowie’s academic life and public lectures cover a broad range of interdisciplinary topics that relate to the human condition: psychiatry, psychotherapy, trauma, continental philosophy, philosophy of mind, anthropology, health and wellbeing, and human optimisation.
He holds dual PhDs, receiving a PhD in Psychiatry from Monash University and a PhD in Philosophy from the University of Melbourne.
Wade Davis is a writer and photographer whose work has taken him from the Amazon to Tibet, Africa to Australia, Polynesia to the Arctic. Explorer-in-Residence at the National Geographic Society from 2000 to 2013, he is currently Professor of Anthropology and the BC Leadership Chair in Cultures and Ecosystems at Risk at the University of British Columbia.
Wade has authored 22 books, including One River, The Wayfinders and Into the Silence, he holds degrees in anthropology and biology and received his Ph.D. in ethnobotany, all from Harvard University. In 2016, he was made a Member of the Order of Canada. In 2018 he became an Honorary Citizen of Colombia.
Rick Doblin, Ph.D., is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard’s Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his Master’s thesis on a survey of oncologists about smoked marijuana vs. the oral THC pill in nausea control for cancer patients. His undergraduate thesis at New College of Florida was a 25-year follow-up to the classic Good Friday Experiment, which evaluated the potential of psychedelic drugs to catalyze religious experiences. He also conducted a thirty-four year follow-up study to Timothy Leary’s Concord Prison Experiment. Rick studied with Dr Stanislav Grof and was among the first to be certified as a Holotropic Breathwork practitioner. His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist. He founded MAPS in 1986, and currently resides in Boston with his wife and empty rooms from three children who are all in college or recently graduated.
James Fadiman B.A. (Harvard) M.A., Ph.D. (Stanford) began his personal psychedelic research a few weeks before starting his graduate work at Stanford where he did his dissertation on the effectiveness of LSD-assisted therapy. During the research lull of 40 years, he has held a variety of teaching (San Francisco State, Brandeis, and Stanford) consulting, training, counseling and editorial positions. He has taught in psychology departments, design engineering, and for three decades, at the Institute of Transpersonal Psychology (now Sofia University) that he co-founded.
He has published textbooks, professional books, a self-help book, a novel, and a series of videos, Drugs: the children are choosing for National Public Television. His books have been published in 8 languages. He has been the subject of a one-hour documentary released by Page3 Films, featured in a National Geographic documentary and had three solo shows of his nature photography.
He had his own consulting firm and sat on two non-profit boards as well as having been the president of several small natural resource companies. He has been involved in researching psychedelic for spiritual, therapeutic and creative uses and is known for his pioneering work on microdosing . He has published The Psychedelic Explorer’s Guide: Safe, Therapeutic, and Sacred Journeys, and most recently, Your Symphony of Selves: Discover and Understand More of Who You Are
Albert Garcia-Romeu, Ph.D. is a member of the Psychiatry and Behavioral Sciences faculty at the Johns Hopkins University School of Medicine and a Guest Researcher at the National Institute on Drug Abuse Intramural Research Program. His research examines the effects of psychedelics in humans, with a focus on psilocybin as an aid in the treatment of addiction. He received his doctorate in Psychology in 2012 from the Institute of Transpersonal Psychology in Palo Alto, CA, where he studied self-transcendence and meditation, and their relationship to mental health. His current research interests include clinical applications of psychedelics, mindfulness, and altered states of consciousness and their underlying psychological mechanisms. He additionally studies real-world drug use patterns and impacts on public health, and the role of spirituality in mental health and addiction. He is a founding member of the Johns Hopkins Center for Psychedelic and Consciousness Research and the International Society for Research on Psychedelics.
Dr Ingmar Gorman is the co-founder of Fluence, a psychedelic education company training mental health providers in psychedelic treatments. He is a psychologist specializing in helping people who use psychedelics and other psychoactive compounds. He received his clinical training at the New School for Social Research, Mount Sinai Beth Israel Hospital, Columbia University, and Bellevue Hospital. He completed his NIH postdoctoral fellowship at New York University in 2017. Dr Gorman was formerly the Director of the Psychedelic Education and Continuing Care Program, formerly site co-principal investigator and current active therapist on a Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder and active therapist on a Phase 2 clinical trial of Psilocybin-assisted Psychotherapy for Treatment Resistant Depression.
Mendel Kaelen is the founder and CEO of Wavepaths. Prior to this, he worked as a PhD and postdoctoral neuroscientist at Imperial College London for 7 years, where his research was the first to demonstrate music’s central role in psychedelic therapies. He developed methods and protocols for the use of music to enhance therapy outcomes and out of this, the vision for Wavepaths. He is a thought leader on the therapeutic use of music and publishes and speaks frequently on this topic. He has been featured in Nature News, San Francisco Chronicles, Vice Motherboard, Rolling Stone and TEDx. Mendel’s work is driven heavily by his personal work with psychedelic medicines and psychotherapies that started 15 years ago. He lives and works in London (UK), and in his spare time likes to get into nature, and to get out of his mind with his Shakuhachi and modular synthesiser.
BA, MD, Doctor of Laws (honoris causa)
Gabor Maté (pronunciation: GAH-bor MAH-tay) is a retired physician who, after 20 years of family practice and palliative care experience, worked for over a decade in Vancouver’s Downtown East Side with patients challenged by drug addiction and mental illness. The bestselling author of four books published in twenty-five languages, Gabor is an internationally renowned speaker highly sought after for his expertise on addiction, trauma, childhood development, and the relationship of stress and illness.
His book on addiction received the Hubert Evans Prize for literary non-fiction. For his groundbreaking medical work and writing he has been awarded the Order of Canada, his country’s highest civilian distinction, and the Civic Merit Award from his hometown, Vancouver. His books include In the Realm of Hungry Ghosts: Close Encounters With Addiction; When the Body Says No; The Cost of Hidden Stress; Scattered Minds: The Origins and Healing of Attention Deficit Disorder; and (with Gordon Neufeld) Hold on to Your Kids: Why Parents Need to Matter More Than Peers. To learn more, join his enews list at www.drgabormate.com.
David E. Nichols, PhD is an Adjunct Professor of Chemical Biology and Medicinal Chemistry at the University of North Carolina, Chapel Hill. Previously he held the Robert C. and Charlotte P. Anderson Distinguished Chair in Pharmacology and was a Distinguished Professor of Medicinal Chemistry and Molecular Pharmacology at the Purdue University College of Pharmacy. He received his B.S. degree in chemistry from the University of Cincinnati in 1969, and the PhD in Medicinal Chemistry from the University of Iowa in 1973, following which he did postdoctoral work in pharmacology at the University of Iowa, College of Medicine. In 2004 he was named the Irwin H. Page Lecturer by the International Society for Serotonin Research and in 2006 he received the first Provost’s Outstanding Graduate Mentor award from Purdue University. He has published more than 300 scientific articles, most of which deal with the relationship between molecular structure and biological action.
BA, MB BChir, MRCP, MA, DM, MRC Psych, FRCPsych, FMedSci, FRCP, FSB
Renowned researcher, policy advisor and author, Professor David Nutt, is currently Head of Neuropsychopharmacology at Imperial College London.
Under the leadership of Professor Nutt, the Psychedelic Research Group at Imperial College is one of the world’s foremost psychedelic research laboratories, publishing landmark research on psychedelic therapies and neuroimaging studies of the psychedelic state.
Professor Nutt has also held many leadership positions in both UK and European academic, scientific and clinical organisations, including presidencies of: the European Brain Council, the British Neuroscience Association, the British Association of Psychopharmacology, the European College of Neuropsychopharmacology.
He was previously Chair of the UK Advisory Council on the Misuse of Drugs.
William A. Richards (Bill), a psychologist in the Center for Psychedelic
and Consciousness Research at the Johns Hopkins School of Medicine, has been
implementing research studies with psilocybin since 1999. His graduate degrees
include M.Div. (Yale) , S.T.M. (Andover-Newton) and Ph.D. (Catholic
University). He also studied with Abraham Maslow at Brandeis University and
with Hanscarl Leuner at Georg-August University in Göttingen, Germany, where
his involvement with psilocybin research originated in 1963. From 1967 to 1977,
he implemented projects of psychotherapy research with LSD, DPT, MDA and
psilocybin at the Maryland Psychiatric Research Center, including protocols
designed to investigate the promise of psychedelics in the treatment of alcoholism,
depression, narcotic addiction and the psychological distress associated with
terminal cancer, and also their use in the training of religious and mental-health
professionals. His book, Sacred Knowledge: Psychedelics and Religious
Experiences has been released by Columbia University Press.
MBBS, B.SC, MRC PSYCH
Ben Sessa is a consultant child and adolescent psychiatrist who has worked with young people and adults in the field of addictions and trauma-related psychiatry for over 20 years. For the last 15 years Ben has been at the forefront of psychedelic research in the UK through his affiliations with Bristol University and Imperial College London, under the auspices of Professor David Nutt. He has taken part as a study doctor and as a healthy subject both receiving and / or administering MDMA, psilocybin, LSD, DMT and ketamine in multiple UK research studies. He runs one of the first UK-based medical cannabis prescribing clinics. Ben is the Chief Medical Officer at AWAKN Life Sciences, a new start-up company opening Europe’s first psychedelic medical clinic, which will be providing psychedelic therapies, therapist training courses and conducting independent research. Ben is the co-founder and former president of Europe’s largest psychedelic conference, Breaking Convention.
Jeremy Weate has a PhD in philosophy from the University of Warwick. He has over 17 years strategic advisory experience, focused on minister-level guidance on the mining sector across over 50 projects in over 30 countries in Europe, Africa, Central Asia and the South Pacific. Jeremy also has a decade-long interest in the medicalization of ibogaine. In 2018, he helped set up Tabula Rasa Retreat in Portugal, now of the leading ibogaine treatment facilities globally. He has organised ibogaine conferences in Vienna, Porto and London. He is CEO of the Vancouver-based Universal Ibogaine, which will IPO on the Toronto Stock Exchange later this year. Universal Ibogaine will take ibogaine through clinical trials in Canada, with a view to multi-country phase 3 trials in Canada, Australia, New Zealand and Israel. The company will launch holistically minded psychedelic-assisted therapy clinics in North America and subsequently globally this decade under the ClearSky Recovery brand.
BPharm, PH.D, FAA, FAHMS
Arthur Christopoulos is Professor of Analytical Pharmacology, Dean of the Faculty of Pharmacy & Pharmaceutical Sciences, and Director of the Neuromedicines Discovery Centre, Monash University, Parkville, Australia. Prior to his appointment as Dean, he was a Senior Principal Research Fellow of the NHMRC. His work focuses on novel paradigms of drug action at G protein-coupled receptors, the largest drug-target class for current medicines, and has been applied to fundamental and translational studies encompassing neurological and psychiatric disorders, cardiovascular disease, obesity, diabetes and chronic pain.
Professor Christopoulos has over 340 publications, including in leading journals such as Nature, Science and Cell. He has also been the recipient of multiple major national and international awards. Since 2014-present, Clarivate Analytics have named him a Highly Cited Researcher in Pharmacology and Toxicology, and in 2021 also named him a Highly Cited Researcher in Biology & Biochemistry. In 2017, he was elected a Fellow of the Australian Academy of Health and Medical Sciences and in 2021 was elected a Fellow of the Australian Academy of Science.
MBBS MPM FRANZCP Cert. Old Age Psych. AFRACMA
Eli is a consultant psychiatrist, holds an academic position at Monash University through the Alfred Psychiatry Research Centre, and is the medical director of Malvern Private Hospital, the first addiction hospital in Australia. He is a member of the Australasian Professional Society on Alcohol and other Drugs (APSAD). Clinically, Eli is interested in the deep connections between trauma and addiction and works within a neuro-psychoanalytic framework. Eli has overseen the development of a clinical program for addictions focused on trauma, particularly developmental trauma. This has led to an interest in medication-assisted trauma therapy. Eli worked for many years researching neurodegenerative diseases and was the principle investigator on numerous trials for novel therapeutics. He is founding member of the Melbourne Neuropsychoanalytic Group and welcomes new members. Through involvement with Monash University, Eli oversees the addiction rotation for medical students.
Eli graduated from the first intake of the Certificate in Psychedelic-Assisted Therapies (CPAT) in June 2021. He has also been recently appointed as the Principal Investigator to lead Emyria’s upcoming MDMA trial.
Dave is a Counselling Psychologist with over 30 years of experience and is one of the directors of Misso Psychology & Consulting. Prior to commencing private practice in 2004, Dave managed one of Australia’s largest counselling agencies and occupied key advisory positions for Australian state and federal governments, including membership on the Queensland Domestic Violence Council. Dave incorporates systems theory, narrative therapy, solution-focused brief therapy, cognitive behaviour therapy, mindfulness, sensorimotor approaches and modern consciousness research in his therapeutic practice, training and supervision. As a business consultant, Dave has worked with a wide range of industries in facilitating organizational strategic planning, leadership development and coaching with executive, senior and middle-level managers.
Dave is a board-approved supervisor with the Psychology Board of Australia and a clinical supervisor for the Australian Government’s Veterans and Veterans Families Counselling Services. He is currently the chair for the Australian Psychological Society College of Counselling Psychology (Qld) and is conducting postgraduate research at QUT investigating individual functioning in male perpetrators of domestic violence.
Donna is a workshop facilitator and has worked in the Human Services field for over 25 years. Prior to establishing Misso Psychology & Consulting, Donna was involved in community services management in organisations that delivered counselling, education and training programs for individuals, couples, and families. Her work in project management was instrumental in developing systems to help strengthen service delivery in these organisations. Donna’s skills in this area were also utilised by the State and Federal governments to assist in implementing Quality Assurance Systems for government-funded community-based organisations.
Donna is a Co-Director of Misso Psychology & Consulting and conducts workshops that utilise sensorimotor and mindfulness-based approaches in working with people who have been affected by trauma. She has worked with these approaches extensively in Australia, USA, and Europe. She has a Bachelor of Human Services majoring in Child and Families, qualifications in counselling, and a Diploma of Community Services Management.
MORE TEACHERS TO BE ANNOUNCED... please watch this space
Mind Medicine Institute has developed a safe and professional psychological service for those who want support regarding psychedelics, plant medicines, and their emotional health and wellbeing.
By submitting an enrolment application for the Certificate in Psychedelic-Assisted Therapies (CPAT), you acknowledge that you have read and accepted these Terms and Conditions.
*Subject to regulatory requirements
Mind Medicine Australia is seeking to establish safe and effective psychedelic-assisted therapies for the treatment of mental illness in Australia. MMA is focused specifically on the clinical application of medicinal psilocybin and medicinal MDMA for the treatment of certain mental illnesses.
We do not advocate for recreational use of psychedelics, MDMA, or any other prohibited substances*, nor do we advocate for any changes to the law with respect to recreational use. Our focus is wholly clinical.
Mind Medicine Australia requires allied health professionals, psychotherapists and general participants wishing to participate in the Certificate in Psychedelic-Assisted Therapies to agree to the following Code of Conduct during the professional development program.
Participants will not:
Failure to follow these guidelines could result in losing a place in the CPAT program.
Thank you for working with us to ensure that we deliver a high quality, safe and reputable CPAT program.
* Psychedelics or psychedelic substances are described as ‘psychoactive substances’ by the Victoria State Government.